Your browser doesn't support javascript.
loading
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Friedman, Claire F; Spencer, Christine; Cabanski, Christopher R; Panageas, Katherine S; Wells, Daniel K; Ribas, Antoni; Tawbi, Hussein; Tsai, Katy; Postow, Michael; Shoushtari, Alexander; Chapman, Paul; Karakunnel, Joyson; Bucktrout, Samantha; Gherardini, Pier; Hollmann, Travis J; Chen, Richard O; Callahan, Margaret; LaVallee, Theresa; Ibrahim, Ramy; Wolchok, Jedd.
Afiliación
  • Friedman CF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA friedmac@mskcc.org.
  • Spencer C; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
  • Panageas KS; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
  • Wells DK; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Ribas A; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
  • Tawbi H; Department of Medicine, University of California Los Angeles, Los Angeles, California, USA.
  • Tsai K; Department of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Postow M; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Shoushtari A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Chapman P; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Karakunnel J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Bucktrout S; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Gherardini P; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Hollmann TJ; Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Chen RO; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
  • Callahan M; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
  • LaVallee T; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
  • Ibrahim R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Wolchok J; Personalis Inc, Menlo Park, California, USA.
J Immunother Cancer ; 10(1)2022 01.
Article en En | MEDLINE | ID: mdl-35074903
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ipilimumab / Nivolumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Ipilimumab / Nivolumab / Inhibidores de Puntos de Control Inmunológico / Melanoma Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos